NCT03388346View on ClinicalTrials.gov

68Ga PSMA in Preprostatectomy Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 16, 2018

Primary Completion Date

July 22, 2021

Study Completion Date

July 22, 2021

Conditions
Prostate CancerProstatic NeoplasmProstatic Neoplasms, Castration-ResistantProstatic Neoplasm of Uncertain Behavior
Interventions
DRUG

Ga-68 PSMA-HBED-CC PET

Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

All Listed Sponsors
collaborator

Holden Comprehensive Cancer Center

OTHER

collaborator

University of Iowa

OTHER

lead

Michael Graham PhD, MD

OTHER

NCT03388346 - 68Ga PSMA in Preprostatectomy Patients | Biotech Hunter | Biotech Hunter